StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a report issued on Wednesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Shares of NASDAQ:TTNP opened at $4.61 on Wednesday. Titan Pharmaceuticals has a 1-year low of $4.24 and a 1-year high of $14.80. The business has a 50-day moving average price of $5.69 and a two-hundred day moving average price of $6.14.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- Differences Between Momentum Investing and Long Term Investing
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What is the Hang Seng index?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
